四问创新药目录申报：哪些药品符合资质？价格谈判由谁主导？

Core Viewpoint - The new commercial health insurance innovative drug directory will respect the market position of commercial health insurance companies, with the first synchronization of the commercial and basic medical insurance directories set for 2025 [1][2]. Group 1: Overview of the Innovative Drug Directory - The first version of the commercial health insurance innovative drug directory will include innovative drugs that are not covered by the basic directory but have high innovation and clinical value, benefiting patients significantly [2]. - The directory will undergo dynamic adjustments based on the development of medical technology, clinical needs, and the evolution of commercial health insurance [2]. Group 2: Application and Review Process - The application process for the commercial health insurance innovative drug directory began in July, with a formal review phase to follow [1][3]. - The review process consists of five stages: preparation, application, expert review, negotiation, and public announcement, with the application phase completed in July and expert review scheduled for August to September [3][6]. Group 3: Expert Involvement and Decision-Making - Experts from various fields, including commercial insurance management, will participate in the review and price negotiation processes, ensuring that commercial health insurance companies have significant decision-making power [7]. - The expert groups will include those responsible for reviewing drug applications, calculating prices, and negotiating with pharmaceutical companies [7]. Group 4: Coordination Between Basic and Commercial Insurance - The establishment of the commercial health insurance innovative drug directory aims to clarify the boundaries of basic medical insurance, allowing for more development space for commercial health insurance [8]. - The National Medical Insurance Administration plans to enhance coordination between basic medical insurance and commercial health insurance through collaborative efforts in coverage, data sharing, settlement, and regulation [9][10].